Thursday newspaper round-up: HSBC, RBS, Pharmacyclics
HSBC boss Stuart Gulliver apologised to MPs on Wednesday for the “unacceptable events” at the bank’s Swiss subsidiary following revelations about tax-avoidance activities in the mid-2000s, reports The Independent. He said it had caused “damage to trust and confidence” in the company.
ALPHABET-A
$156.00
13:10 25/04/24
Banks
4,042.13
09:50 26/04/24
DJ EURO STOXX 50
4,939.01
23:59 25/04/24
Dow Jones I.A.
38,085.80
04:30 15/10/20
FTSE 100
8,109.31
09:50 26/04/24
FTSE 350
4,455.34
09:50 26/04/24
FTSE All-Share
4,408.81
09:50 26/04/24
HSBC Holdings
661.90p
09:50 26/04/24
Iberdrola
€11.46
18:16 25/04/24
IBEX 35
11,070.50
18:45 25/04/24
Johnson & Johnson
$146.82
11:09 25/04/24
Nasdaq 100
17,430.50
12:15 25/04/24
NATWEST GROUP
304.20p
09:50 26/04/24
RBS’s chief executive Ross McEwan is to hand back £1m of his annual pay package, saying he did not want to receive the “role-based” shares incentive, according to The Guardian.
US cancer drugs manufacturer Pharmacyclics is said to be considering a sale that could value it at $19bn, the Financial Times said. According to the paper’s sources, Johnson & Johnson is exploring a deal with the company.
According to the Wall Street Journal, Google and merged its European operations into a single business “to better align the business with large customers and develop more unified responses to rising regulatory pressure in the region”.
Terra Firma is planning to start a sale of its European cinema chain, Odeon & UCI Group, at the end of the year, reports The Telegraph. The deal could be worth £1bn.
Iberdrola, the Spanish power utility group, has agreed to buy US power and gas distributor UIL Holdings for $52.83 a share, valuing the group at $3bn, the Wall Street Journal reports.
Russia has threatened to disrupt gas supplies to Europe as it demanded immediate advance payments from Ukraine, writes The Times.